Neuraminidase

Neuraminidase, Microorganism (Exo-α-sialidase) is a sialidase that catalyzes the hydrolysis of sialic acid, has antigenic properties, and assists in the separation of mature influenza viruses from the host cell to infect new cells.Sodium caseinates is used as a thickening and emulsifying agent in the food industry.

Neuraminidase-IN-1 (Compound Y-1) is a novel neuraminidase inhibitor.

Laninamivir octanoate (CS-8958) is a long acting influenza neuraminidase (NA) inhibitor which shows superior anti-influenza virus activity.

Neuraminidase-IN-22 (compound 3e) serves as a potent, selective, and orally active inhibitor of neuraminidase, exhibiting a low IC 50 value of 0.03 µM. This compound demonstrates cytotoxic effects and possesses activity against the influenza A virus.

Neuraminidase-IN-23 (33c) is a potent inhibitor of the neuraminidase enzyme (NA) targeted against influenza viruses. It exhibits inhibitory concentration (IC50) values of 0.049 μM for H1N1, 0.26 μM for H3N2, 0.17 μM for H5N1, 0.013 μM for H5N8, and 0.74 μM for H5N1-H274Y.

Neuraminidase-IN-15 is an inhibitor of neuraminidase, effectively suppressing the activity of La Sota Clone 30 NDV-HN with an IC50 value of 0.06 µM. Neuraminidase-IN-15 is applicable for studies on Newcastle disease virus (NDV).

Neuraminidase-IN-20 (Compound 5i) is an inhibitor of neuraminidase (NA)(H5N1-H274Y) with an IC50 of 0.44 μM. It binds to the 430-cavity site of NA, disrupting the enzyme's activity.

Neuraminidase-IN-19 (compound 5n) is a neuraminidase inhibitor featuring a thiophene ring, with an IC50 of 0.13 μM, and exhibits anticancer cell activity.

Neuraminidase-IN-6 (Compound 5c), a derivative of 1,3,4-triazole-3-acetamide, is a potent neuraminidase inhibitor with an IC50 value of 0.11 μM, making neuraminidase (NA) an ideal target for anti-influenza drug development [1].

Neuraminidase-IN-5 (Compound 5b), a dihydrofurocoumarin derivative, acts as a potent neuraminidase (NA) inhibitor, exhibiting significant inhibition with an IC 50 of 0.02 μM. Given NA's role in influenza pathogenesis, this compound emerges as a promising candidate for anti-influenza drug development [1].

Neuraminidase-IN-8 (Compound 6d) is a potent neuraminidase inhibitor with a low IC50 of 0.027 μM, demonstrating significant anti-influenza activities [1].

Neuraminidase-IN-4 (Compound 4b) is a potent inhibitor of neuraminidase (EC50: 1.59 μM) and exhibits significant antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW).

Neuraminidase-IN-7 (compound 4b), a thiophene derivative, is a potent neuraminidase inhibitor (IC50: 0.03 μM) with potential applications in influenza research.

Neuraminidase-IN-3 (compound 23d) is a potent inhibitor of influenza neuraminidase (NA) with IC50 values of 0.73 nM for H1N1, 0.26 nM for H5N1, and 0.63 nM for H5N8 NAs.

Neuraminidase-IN-10 is a neuraminidase inhibitor that exhibits anti-influenza effects and is able to act on H1N1 (IC50: 2.6 nM), H5N1 (IC50: 5.1 nM) and H5N8 (IC50: 1.65 nM).

Neuraminidase-IN-9 (Compound 6l) is a potent inhibitor of influenza virus neuraminidase, targeting H5N1 (IC50: 0.12 μM), H5N2 (IC50: 0.049 μM), and H5N6 (IC50: 0.16 μM).

Neuraminidase-IN-11 (15e) is a selective and potent neuraminidase (NA) inhibitor, effective against the neuraminidase of H1N1 virus (IC50: 4.7 nM), H5N1 virus (IC50: 8.46 nM), and H5N8 virus (IC50: 1.5 nM).

NDV-IN-1 is an antiviral agent with high neuraminidase inhibitory activity, demonstrating significant in vitro inhibitory effects against Newcastle disease virus (NDV). It effectively prevents NDV infection of Vero cells by inhibiting the release of virus particles from infected cells [1].

Neuraminidase-IN-16 (Compound 43b) serves as a potent inhibitor of neuraminidase, demonstrating IC50 values of 0.031, 0.15, 0.25, 0.60, 0.63, and 10.08 μM against neuraminidase from H5N1, H5N8, H1N1, H3N2, H5N1–H274Y, and H1N1–H274Y strains, respectively [1].

Neuraminidase-IN-13 (Compound 10), a neuraminidase inhibitor exhibiting antiviral activity, demonstrates significant inhibition of NDV infection in Vero cells with minimal cytotoxicity by impeding the release of viral particles from infected cells [1].

Neuraminidase-IN-17 (compound N10), characterized as a neuraminidase inhibitor, demonstrates an EC 50 of 0.11 μM and exhibits antiviral activity in vitro [1].

Neuraminidase-IN-18 (compound N5), a novel polyheterocyclic neuraminidase (NA) inhibitor, demonstrates significant inhibitory activity against H5N1 NA, with an IC 50 of 0.14 μM against the wild-type H5N1 NA and 0.27 μM against the H5N1-H274Y mutant NA. This compound effectively binds to NAs, inhibiting influenza virus replication at the cellular level [1].

Neuraminidase-IN-21 (Compound 6d) is an inhibitor of the influenza H1N1 virus neuraminidase, boasting an IC50 value of 0.30 µM against the neuraminidase enzyme and 30.01 µM against the H1N1 virus strain. It forms three hydrogen bonds with the neuraminidase residues Arg292, Arg371, and Tyr406.

Oseltamivir phosphate (GS 4104) is a neuraminidase (NA) inhibitor with oral activity. Oseltamivir phosphate has antiviral activity and is effective against a wide range of influenza viruses, inhibiting mature influenza viruses from breaking away from host cells.